Adrenal insufficiency and checkpoint inhibitors for cancer
==========================================================

* Daniel L Morganstein
* James Larkin

Editor – Simpson *et al* provide a welcome overview of the importance of the recognition and treatment of adrenal insufficiency.1 However, there is no mention of checkpoint inhibitors for cancer, which have emerged as an important and common cause of secondary adrenal insufficiency, and rarely primary adrenal insufficiency.2 The importance and challenge of prompt recognition has been recognised.3 Checkpoint inhibitors are approved globally for the treatment of multiple different cancer types, including non-small-cell lung carcinoma, melanoma, bladder, kidney, and head and neck cancers. Given that around 10% of patients treated with ipilimumab, and 1–2% of patients treated with PD-1/PD-l1 inhibitors develop adrenocorticotropic hormone (ACTH) deficiency, we propose that all patients with current or recent checkpoint inhibitor use should be included in those considered at risk of an adrenal crisis.

In addition, a third of patients receiving a checkpoint inhibitors will require high does corticosteroids for management of one or more immune related adverse events and it is vital that oncological practice takes on the need to issue these patients with the new steroid card and appropriate education.4,5

*   © Royal College of Physicians 2020. All rights reserved.

## References

1.  1.  Tomlinson J
    
    
    
    
    1.  Wass J, 
    2.  et al
    
    Simpson H, Tomlinson J, Wass J, et al. Guidance for the prevention and emergency management of adult patients with adrenal insufficiency. Clin Med 2020;20;371–8.
    
    [Abstract/FREE Full Text](http://www.rcpjournals.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MTI6ImNsaW5tZWRpY2luZSI7czo1OiJyZXNpZCI7czo4OiIyMC80LzM3MSI7czo0OiJhdG9tIjtzOjMwOiIvY2xpbm1lZGljaW5lLzIwLzUvZTEzOS4xLmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 

2.  1.  Newsom-Davis T
    
    
    
    
    1.  Morganstein DL
    
    Nogueira E, Newsom-Davis T, Morganstein DL. Immunotherapy-induced endocrinopathies: assessment, management and monitoring. Ther Adv Endocrinol Metab 2019;10:2042018819896182.
    
    

3.  1.  Olsson-Brown A
    
    
    
    
    1.  Carroll P, 
    2.  et al
    
    Higham CE, Olsson-Brown A, Carroll P, et al. Society for Endocrinology endocrine emergency guidance: Acute management of the endocrine complications of checkpoint inhibitor therapy. Endocrine Connections 2018;7:G1–7.
    
    [Abstract/FREE Full Text](http://www.rcpjournals.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MTE6ImVuZG9jb25uZWN0IjtzOjU6InJlc2lkIjtzOjY6IjcvNy9HMSI7czo0OiJhdG9tIjtzOjMwOiIvY2xpbm1lZGljaW5lLzIwLzUvZTEzOS4xLmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 

4.  1.  Yousaf N
    
    
    
    
    1.  Morganstein D
    
    Agarwal K, Yousaf N, Morganstein D. Glucocorticoid use and complications following immune checkpoint inhibitor use in melanoma. Clin Med 2020;20:163–8.
    
    [Abstract/FREE Full Text](http://www.rcpjournals.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MTI6ImNsaW5tZWRpY2luZSI7czo1OiJyZXNpZCI7czo4OiIyMC8yLzE2MyI7czo0OiJhdG9tIjtzOjMwOiIvY2xpbm1lZGljaW5lLzIwLzUvZTEzOS4xLmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 

5.  1.  Adel NG
    
    
    
    
    1.  Dang T-O, 
    2.  et al
    
    Horvat TZ, Adel NG, Dang T-O, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol 2015;33:3193–8.
    
    [Abstract/FREE Full Text](http://www.rcpjournals.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiamNvIjtzOjU6InJlc2lkIjtzOjEwOiIzMy8yOC8zMTkzIjtzOjQ6ImF0b20iO3M6MzA6Ii9jbGlubWVkaWNpbmUvMjAvNS9lMTM5LjEuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9)